Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan;21(1):46-56.
doi: 10.1038/s41575-023-00846-4. Epub 2023 Oct 5.

Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease

Affiliations
Review

Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease

Gong Feng et al. Nat Rev Gastroenterol Hepatol. 2024 Jan.

Abstract

Recompensation has gained increasing attention in the field of cirrhosis, particularly in chronic liver disease with a definite aetiology. The current global prevalence of obesity and nonalcoholic fatty liver disease (NAFLD) is increasing, but there is currently a lack of a clear definition for recompensation in NAFLD-related cirrhosis. Here, we provide an up-to-date perspective on the natural history of NAFLD, emphasizing the reversible nature of the disease, summarizing possible mechanisms underlying recompensation in NAFLD, discussing challenges that need to be addressed and outlining future research directions in the field. Recompensation is a promising goal in patients with NAFLD-related cirrhosis, and further studies are needed to explore its underlying mechanisms and uncover its clinical features.

PubMed Disclaimer

References

    1. Schuppan, D. & Afdhal, N. H. Liver cirrhosis. Lancet 371, 838–851 (2008). - PubMed - PMC
    1. Mauro, E. & Gadano, A. What’s new in portal hypertension? Liver Int. 40, 122–127 (2020). - PubMed
    1. Xu, X. et al. Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study. BMJ Open 11, e043083 (2021). - PubMed - PMC
    1. Cheung, M. C. M. et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J. Hepatol. 65, 741–747 (2016). - PubMed
    1. Gentile, I. et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity–LINA cohort). Hepatol. Int. 13, 66–74 (2019). - PubMed

LinkOut - more resources